Navigation Links
Duke awarded up to $43 million to develop test for dirty bomb/radiation exposure
Date:1/20/2010

DURHAM, N.C. Duke University has received a $3.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid and accurate genomic-based diagnostic test that can determine if a person has been exposed to radiation from a dirty bomb or nuclear attack. In the event that all option years are exercised by the government, Duke University could receive up to $43.6 million from the contract.

"Since 9/11, there has been national concern about the possibility of a terrorist attack in the U.S. involving radiological or nuclear materials. Such an attack could kill or injure hundreds of thousands of people," says John Chute, M.D., associate professor of medicine at Duke and principal investigator of the project. "The problem is that right now, we don't have any way to rapidly screen thousands of people to determine their level of radiation exposure. Many people who suffer radiation injury can recover and survive if they are promptly and properly treated."

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. It manages Project BioShield and the Public Health Emergency Medical Countermeasures Enterprise, two organizations charged with the development of medical response to pandemic disease and countermeasures for chemical, biological and nuclear attacks.

The award builds upon Chute's previous collaborations at Duke with Joseph Nevins, Ph.D. and Nelson Chao, M.D. that identified a set of 25 genes in human peripheral blood that are activated in response to radiation. Chute says that radiation exposure causes a characteristic pattern of expression in those 25 genes and this "signature" can diagnose radiation status with over 90 percent accuracy. Chute's earlier work was supported by a $25 million grant from the National Institutes of Allergy and Infectious Diseases that established the Duke Center for Medical Countermeasures Against Radiation, now in its fifth year of funding.

The new contract calls for Chute and his team at Duke to further validate the accuracy of the gene profile in animal and human testing. Collaborators at DxTerity Diagnostics, a biotechnology company based in California, will utilize the Duke gene panel to develop a rapid gene expression test while colleagues at the University of Arizona and Invetech Corporation will design and develop the instrument in which the assay will be performed. The end product will be a portable, 30-minute test for radiation injury that can be used to triage thousands of individuals in a short time following a radiological or nuclear attack.

"The Homeland Security Council document, 'Planning Guidance for Response to a Nuclear Detonation' indicates that a 10-kiloton improvised nuclear device would likely be lethal to individuals within about a half-mile radius of the blast," says Chute. "Outside this zone, however, thousands of individuals would be exposed to high-dose radiation but may be able to survive with prompt medical intervention. Further from the blast area, there would be additional thousands who have suffered little or no exposure, and may not need medical attention, but who will still be seeking it."

Chute says that such a scenario will require early and accurate triage of mass casualties to provide an effective health care response. "Imagine a blast zone with a ring of triage stations at the perimeter. We believe that using our diagnostic assay in such points would allow us to screen tens of thousands of individuals in a 24-hour period and to distinguish true radiation victims from the uninjured," says Chute.

Chute says the assay will involve a single collection of only a few drops of blood that will be analyzed in a fully automated instrument with each result provided in about 30 minutes. That dramatically shortens the time it currently takes to analyze large numbers of genes, a process that takes several days and requires large equipment. Researchers hope to have a prototype ready for demonstration by 2012.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related biology news :

1. Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant awarded to Johns Hopkins Early Career investigator
2. Cylex(TM) Awarded New CPT Code For Its ImmuKnow(R) Assay
3. LSUHSC awarded multi-million dollar grant to reduce pneumonia
4. K-State plant pathology professor awarded international professorship for Latin America
5. Penn, Georgia collaboration awarded $14.6 million to expand pathogen database
6. Air Force Center of Excellence awarded in nanostructures and improved cognition
7. Stanford researchers awarded $6.27 million to study energy efficiency and human behavior
8. University of Miami facility awarded prestigious LEED Green Building Certification
9. Professor Suzanne Cory awarded 2009 Pearl Meister Greengard Prize
10. UNC awarded $6.2 million renewal grant by NIH Rare Diseases Research Network
11. VBI awarded $27 million from NIH to support infectious disease research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):
(Date:1/16/2017)... LOUISVILLE, Ky. , Jan. 16, 2017  Eurofins ... service, which will allow more customers to receive their ... price premium or compromise in quality found with other ... the United States at no additional ... variety of routine genetic studies, including DNA sequencing, genotyping, ...
(Date:1/13/2017)... ... 13, 2017 , ... Two Kalamazoo entrepreneurs have launched AgTonik ... that farms, greenhouses and hydroponics operations use to increase yields and promote plant ... segments of customers using this high grade fulvic acid extracted from a mineral ...
(Date:1/12/2017)... Ca (PRWEB) , ... January ... ... low-cost, disposable devices with short response times capable of performing routine electrochemical ... fields, disposable screen-printed electrodes provide fast, sensitive detection and quantification of various ...
(Date:1/12/2017)... January 12, 2017 A new report published by Allied Market ... Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro toxicity ... at a CAGR of 15.07% during the forecast period. ... ... ...
Breaking Biology Technology: